Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Biomarkers for Colorectal Liver Metastases Resectability after Cetuximab Chemotherapy
2012-000834-21Phase 2Active
- Sponsor
- Istituti Fisioterapici Ospitalieri
- Start
- Apr 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in colorectal cancer (CRC), sponsored by Istituti Fisioterapici Ospitalieri. Primary endpoint: Complete resection of liver metastases. Started Apr 2012; status: active.
02
Drugs
cetuximab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2012-000834-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000834-21.